T1	Procedure 38 55	histopathological
E1	Procedure:T1 Name:T83
T2	Or 56 58	or
E2	Or:T2 Arg:E1 Arg2:E3
T3	Procedure 59 82	cytological examination
E3	Procedure:T3 Name:T46
T4	Eq-Comparison 136 148	at least one
E4	Eq-Comparison:T4 Operator:T47 Value:T48
T5	Condition 159 165	lesion
E5	Condition:T5 Name:T49 Minimum-Count:E4
T6	Eq-Comparison 215 223	received
E6	Eq-Comparison:T6 Temporal-Period:T50
T7	Procedure 230 239	treatment
E7	Procedure:T7 Temporality:E6
T8	Eq-Comparison 278 297	previously received
E8	Eq-Comparison:T8 Temporal-Period:T51
T10	Drug 298 330	anti-programmed death receptor-1
E10	Drug:T10 Name:T53 Temporality:E8
T11	Drug 332 336	PD-1
E11	Drug:T11 Name:T54
T12	Modifier 338 346	antibody
E12	Modifier:T12 Modifies:T53
T14	Drug 348 378	anti-programmed death ligand-1
E14	Drug:T14 Name:T55
T15	Drug 380 385	PD-L1
E15	Drug:T15 Name:T56
T16	Modifier 387 395	antibody
E16	Modifier:T16 Modifies:T55
T18	Drug 429 434	PD-L2
E18	Drug:T18 Name:T60
T19	Modifier 436 444	antibody
E19	Modifier:T19 
T20	Or 445 447	or
E20	Or:T20 Arg:E18 Arg2:E21
T21	Drug 448 496	anti-cytotoxic T lymphocyte-associated antigen-4
E21	Drug:T21 Name:T62
T22	Drug 498 504	CTLA-4
E22	Drug:T22 Name:T63
T24	Study 576 581	study
E24	Study:T24 
T25	Eq-Comparison 601 620	previously received
E25	Eq-Comparison:T25 Temporal-Period:T65
T26	Procedure 625 629	TACE
E26	Procedure:T26 Name:T66 Temporality:E25
T27	Procedure 631 654	radiofrequency ablation
E27	Procedure:T27 Name:T67
T28	Or 655 658	and
E28	Or:T28 Arg:E27 Arg2:E30
T29	Other 659 664	other
E29	Other:T29 Is-Other:E30
T30	Procedure 678 688	treatments
E30	Procedure:T30 
T31	Eq-Comparison 711 718	history
E31	Eq-Comparison:T31 Temporal-Period:T69
T32	Condition 722 746	gastroesophageal varices
E32	Condition:T32 Name:T70 Temporality:E31
T33	Or 747 749	or
E33	Or:T33 Arg:E32 Arg2:E35
T34	Eq-Comparison 750 756	active
E34	Eq-Comparison:T34 Temporal-Period:T71
T35	Condition 757 770	cardia ulcers
E35	Condition:T35 Name:T72 Temporality:E34
T36	Risk 794 798	risk
E36	Risk:T36 Polarity:T73 Risk-For:E37
T37	Condition 802 810	bleeding
E37	Condition:T37 Name:T74
T38	Condition 858 868	hemorrhage
E38	Condition:T38 Name:T75 Temporality:E39
T39	Eq-Comparison 869 882	within 1 year
E39	Eq-Comparison:T39 Operator:T76 Value:T77 Temporal-Unit:T78
T40	Condition 926 929	HCC
E40	Condition:T40 Name:T79
T41	Condition 943 946	HCC
E41	Condition:T41 Name:T80
T42	Or 947 949	or
E42	Or:T42 Arg:E41 Arg2:E43
T43	Condition 956 974	cholangiocarcinoma
E43	Condition:T43 Name:T81
T44	Condition 979 982	HCC
E44	Condition:T44 Name:T82
T46	Procedure-Name 59 82	cytological examination
T47	Eq-Operator 136 144	at least
A1	Eq-Operator-Value T47 GTEQ
T48	Eq-Value 145 148	one
T49	Condition-Name 159 165	lesion
T50	Eq-Temporal-Period 215 223	received
A2	Eq-Temporal-Period-Value T50 past
T51	Eq-Temporal-Period 278 297	previously received
A3	Eq-Temporal-Period-Value T51 past
T53	Drug-Name 298 330	anti-programmed death receptor-1
T54	Drug-Name 332 336	PD-1
T55	Drug-Name 348 378	anti-programmed death ligand-1
T56	Drug-Name 380 385	PD-L1
T58	Drug-Name 397 427	anti-programmed death ligand-2
T60	Drug-Name 429 434	PD-L2
T62	Drug-Name 448 496	anti-cytotoxic T lymphocyte-associated antigen-4
T63	Drug-Name 498 504	CTLA-4
T65	Eq-Temporal-Period 601 620	previously received
A9	Eq-Temporal-Period-Value T65 past
T66	Procedure-Name 625 629	TACE
T67	Procedure-Name 631 654	radiofrequency ablation
T68	Condition-Name 671 677	cancer
T69	Eq-Temporal-Period 711 718	history
A10	Eq-Temporal-Period-Value T69 past
T70	Condition-Name 722 746	gastroesophageal varices
T71	Eq-Temporal-Period 750 756	active
A11	Eq-Temporal-Period-Value T71 present
T72	Condition-Name 757 770	cardia ulcers
T73	Polarity 789 793	high
A12	Polarity-Value T73 high
T74	Condition-Name 802 810	bleeding
T75	Condition-Name 858 868	hemorrhage
T76	Eq-Operator 869 875	within
A13	Eq-Operator-Value T76 LTEQ
T77	Eq-Value 876 877	1
T78	Eq-Temporal-Unit 878 882	year
A14	Eq-Temporal-Unit-Value T78 year
T79	Condition-Name 926 929	HCC
T80	Condition-Name 943 946	HCC
T81	Condition-Name 956 974	cholangiocarcinoma
T82	Condition-Name 979 982	HCC
T83	Procedure-Name 38 55	histopathological
T84	Negation 211 214	not
E46	Negation:T84 Negates:E7
T85	Modifier 224 229	local
E47	Modifier:T85 Modifies:E7
T86	Modifier 149 158	evaluable
E48	Modifier:T86 Modifies:T49
T87	And 203 206	and
E49	And:T87 Arg:E5 Arg2:E46
R1	Abbrev-Of Arg1:E11 Arg2:E10	
R2	Abbrev-Of Arg1:E15 Arg2:E14	
T9	Drug 397 427	anti-programmed death ligand-2
E9	Drug:T9 Name:T58
R3	Abbrev-Of Arg1:E18 Arg2:E9	
R4	Abbrev-Of Arg1:E19 Arg2:E9	
R5	Abbrev-Of Arg1:E22 Arg2:E21	
T13	Modifier 506 516	antibodies
E13	Modifier:T13 Modifies:T62
T17	Condition 671 677	cancer
E17	Condition:T17 Name:T68
T23	Modifier 665 670	liver
E23	Modifier:T23 Modifies:T68
R6	Treatment-For Arg1:E30 Arg2:E17	
R7	Caused-By Arg1:E36 Arg2:E35	
T52	Modifier 835 857	upper gastrointestinal
E50	Modifier:T52 Modifies:T75
T57	Modifier 931 942	sarcomatoid
E51	Modifier:T57 Modifies:T80
T59	Modifier 912 925	fibrous layer
E52	Modifier:T59 Modifies:T79
T61	Modifier 950 955	mixed
E53	Modifier:T61 Modifies:T81
T64	And 975 978	and
E54	And:T64 Arg:E43 Arg2:E44
